Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by wyndeweston Jun 01, 2017 3:00pm
212 Views
Post# 26312756

RE:June 5th is not a final date for priority review

RE:June 5th is not a final date for priority reviewThanks Pierre for the information.  It is confusing as so many on this board have said WITHIN/LATEST 2 months for the FDA to respond (ie. by June 5). Now I think you are saying any time AFTER 2 months from date of submission of BLA (submitted April 5), therefore anytime after June 5.... that scenario sounds realistic by FDA standards and is probably correct. 
Bullboard Posts